Agreements reached under this partnership
Business Alliances- 1
Assessment of the feasibility of applying ultrafine bubble water to ophthalmic drops
- 2
The companies will conduct applied research aimed at developing ophthalmic drops containing drugs that have been difficult to formulate using conventional technologies, as well as creating ophthalmic products based on new concepts, by leveraging the properties of high-concentration UFB water.
- 3
By combining the technologies and expertise held by both companies, the companies will pursue new possibilities for pharmaceutical development in the ophthalmic field.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of entering into this joint research agreement on results for the current fiscal year is currently expected to be limited.
| Item | Details |
|---|---|
| Name of alliance partner | Pharstoma INC. |
| Alliance partner's business activities | Research and development utilizing ultrafine bubble technology, among other activities |
| Alliance partner's location | Minato-ku, Tokyo |
| Type of alliance | Business Alliances |
| Details of the alliance | Assessment of the feasibility of applying ultrafine bubble water to ophthalmic drops, The companies will conduct applied research aimed at developing ophthalmic drops containing drugs that have been difficult to formulate using conventional technologies, as well as creating ophthalmic products based on new concepts, by leveraging the properties of high-concentration UFB water., By combining the technologies and expertise held by both companies, the companies will pursue new possibilities for pharmaceutical development in the ophthalmic field. |
| Alliance start date | As of the disclosure dated 7 September 2026, the disclosure states that the joint research had commenced, but the specific start date is not disclosed. |
| Impact on Business Performance | The impact of entering into this joint research agreement on results for the current fiscal year is currently expected to be limited. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To assess the feasibility of applying UFB water to ophthalmic drops by combining 坪田ラボ's research and development expertise in the ophthalmic field with Pharstoma's high-concentration UFB technology.